ClinicalTrials.gg
Active, not recruitingNCT06155448PMCEffectUpdated Dec 4, 2023

Perennial Malaria Chemoprevention (PMC) Effect Study

An interventional study of Perennial Malaria Chemoprevention effect in Malaria, sponsored by Malaria Consortium. Active, not recruiting at 1 site in Nigeria. Open to participants aged 10 Weeks to 24 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-04.

Sponsored by Malaria Consortium · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 3 months ago, but the record still lists the study as active, not recruiting.
  • Registered 3 months after the study started (first participant enrolled Aug 2023, registered Nov 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,000
Allocation
Randomized
Ages
10 Weeks to 24 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Malaria by Malaria Consortium — 3 open to participants now, 9 under way, 2 of them phase 3. Malaria · Malaria Consortium.

Started
2023
with 3 others
No phase
3 of 10
1 open now
Registered
8th of 10
by date

Among the 10 studies in Malaria by Malaria Consortium, this one is one of 4 that started in 2023, is one of 3 with no phase, and was the 8th registered.

Malaria

1,187 studies on the registry are indexed under Malaria; 80 are open to participants now.

Browse Malaria studies →

Open to participants now

3 of the 10 studies in Malaria by Malaria Consortium are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 51 Malaria studies recruiting now, 15 (29%) set no upper age limit and 33 (65%) stop at 75 or younger; 37 take children under 18; 31 take healthy volunteers.

This study: 10 Weeks to 24 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Malaria by Malaria Consortium, or all of them as a file.
02

Study summary

The Malaria Consortium Nigeria (MC) will coordinate a trial of PMC in Osun State, Nigeria with strategic support from the National Malaria Elimination Programme of the Government of Nigeria (NMEP) and financial support from the BMGF. The primary purpose of the study is to provide evidence of the impact of PMC on malaria burden and related clinical outcomes, and its operational feasibility for policy decision and the inclusion of PMC into upcoming programme and funding cycles for its National Malaria Control Strategic Plan. The objectives are:

  1. To evaluate the impact of PMC in children aged 2-18 months on key child health outcomes including malaria burden, hospitalisations, and anaemia.
  2. To describe indicators of operational feasibility of PMC by identification and measurement of key determinants of successful uptake and implementation of PMC.
Read the detailed description

Study Design and Procedures The impact of PMC will be evaluated in a two-arm cluster-randomised controlled trial and nested case control study. The primary impact outcomes are a comparison of the incidence of clinical malaria in children 2-18 months of age visiting selected sentinel primary care facilities in intervention arm and comparison (standard care) arm wards in the study site, and the protective effectiveness of SP in the 28 days following a dose in intervention arm wards. A ward, the lowest level of health services administration for the State, will be the cluster unit of randomisation. A single facility meeting study eligibility criteria will be selected in each ward as the sentinel facility in which study outcomes will be evaluated (bi-monthly extraction of data on confirmed malaria cases by the study team). Strengthened age recording (full age in months) of visiting children will be implemented in each sentinel facility. An identical programme of data collection will take place in secondary and tertiary hospitals which serve the study site and will include data on admissions of children with an address in a study ward.

Cross sectional household 'malariometric' surveys will be conducted in catchment area communities of ;in both arms at baseline, at 18 months following start of PMC implementation, and at 24 months once implementation ends. Data on coverage of PMC doses (main indicator of feasibility) will be collected from child health record cards or caregiver report for children in the age groups eligible to receive the doses in question. Additional data on malaria infection (RDT test) and anaemia prevalence will be collected during the cross sectional surveys.

Collection of malaria data from sentinel facilities for children aged 19 months and older who were eligible to receive PMC during the implementation period (but too old at the end of implementation) will continue for an additional 12 months following the end of implementation period. The potential rebound effects of the intervention will be assessed in this period by a comparison of incidence rates in control and intervention arm wards.

Sample size (impact): The expected reduction in incidence of malaria in children aged 2-18 months after 18 months of implementation is conservatively estimated to be between 18%-32% contingent on the level of coverage of PMC doses in the intervention arm; enrolling 40 wards in each arm (for a total of 80) will provide 90% power to detect an impact of 20% in this age group after 18 months of implementation, and 95% after 24 months of implementation. We will also recruit children aged 2-18m with clinical malaria from 8 of the 40 intervention arm sentinel facilities and match these to 2-4 controls to have 95% power to detect a protective effectiveness of 50% reduction in malaria in the 28 days following a dose of SP.

Sample size (feasibility): To estimate coverage for any dose of 50% with a margin of error of 8%, assuming a design effect of 2.44 based on an implied intra cluster correlation coefficient of 0.18 (Nigeria DHS) to account for the cluster sample strategy, and allowing for 10% non-response, 25 children aged 2-36 months will be required in each cluster (ward), for a total of 25x40=1,000 in each arm of the study and with a total of 2000 across both arms.

Follow-up period: The total follow-up period of implementation will be 24 months, starting April 2023 to March 2025. The primary evaluation of impact and feasibility will occur in the first 18 months of implementation (April 2023 - September 2024).

Description of intervention: Health facility staff will be trained to offer scheduled doses of SP linked to the EPI delivery platform in children aged 10 weeks to 15 months (six doses), plus additional 'pragmatic' monthly doses offered outside of the EPI schedule to children up to 18 months of age (up to eleven additional doses). Additional social mobilisation and social behaviour change (SBC) activities will be conducted throughout the implementation period to increase demand and uptake of vaccination and PMC services in the study population.

Pharmacovigilance: Spontaneous (passive) adverse event (AE) reporting will be implemented in all study facilities (both sentinel and non-sentinel facilities in study wards),and will include training of health facility staff to recognise and manage known potential side effects of SP, and the development of picture based AE cards and posters for families and facility staff. Children with severe AEs will be referred to secondary/tertiary facilities as appropriate. A programme of active AE monitoring in a cohort of children will be additionally implemented in 2 facilities in each intervention arm in order to collect more detailed data on timings and symptoms following PMC or EPI doses, and to compare AE reporting rates between arms.

Additional activities: Cross-sectional health facility surveys and stakeholder interviews will take place during the follow-up period to collect data on implementation outcomes, alongside qualitative data collection in focus group discussions and in-depth interviews.

03

Conditions studied

  • Malaria

Browse trials for

Keywords

  • PMC
  • Chemoprevention
  • Malaria
  • Integrated delivery
04

Who can participate

Ages eligible
10 Weeks to 24 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 10 weeks to 24 months
  • Healthy

Exclusion criteria

Exclusion Criteria:

  • severe acute malnutrition, or
  • allergic to sulphur containing medication,
  • positive,
  • taking cotrimoxazole as prophylaxis or treatment, or SP, or other sulphur-containing medication in the previous 4 weeks, and
  • children with a positive malaria RDT
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,000 participants (estimated)

Study arms

  • Experimental
    PMC intervention

    The PMC intervention is designed to deliver a core regimen of six paediatric doses of sulphadoxine pyrimethamine linked to the EPI delivery platform in children 10 weeks to 15 months of age through trained health facility staff, plus additional 'pragmatic' monthly doses offered outside of the EPI schedule to children up to 18 months of age. Additional social mobilisation and social behaviour change (SBC) activities will be conducted throughout the implementation period to increase demand and uptake of vaccination and PMC services in the study population. at EPI scheduled touchpoints, plus additional monthly doses at non-scheduled monthly intervals up to age 18 months. The primary source of delivery will be government-run primary care health facilities in intervention arm wards. Coordination of implementation of the study within intervention and control arm wards will take place at the LGA level (unit of implementation).

    Other: Perennial Malaria Chemoprevention effect

  • No intervention
    Control

    The control sites will have normal immunization as business as usual. However, the same sentinel site surveillance happening in the intervention arm will also be carried out in this arm. Pharmacovigilance will be passive in the control arm.

Interventions

  • OtherPerennial Malaria Chemoprevention effect

    Assessing the effectiveness and feasibility of Perennial malaria chemoprevention delivery through EPI platform.

    Also known as: PMC effect

06

What researchers measure

Primary outcomes

  1. . Incidence rate of clinical malaria

    Incidence rate of parasitologically-confirmed clinical malaria cases in children 2-18 months presenting to selected sentinel facilities over 18 months\* of implementation.

    Time frame: 18 months

  2. Protective effectiveness of SP

    Protective effectiveness of SP treatments as measured by the percentage reduction in the incidence of malaria associated with receipt of SP in the last 28 days over 18 months\* of implementation

    Time frame: 18 months

Secondary outcomes

  1. Prevalence of malaria infection

    Prevalence of reported malaria in eligible children aged 2-18 months visited in an endline cross-sectional survey after 18m of implementation.

    Time frame: 18 months

  2. Prevalence of anaemia

    Prevalence of anaemia (haemoglobin \<80g/L) in eligible children aged 2-18 months visited in an endline cross-sectional survey after 18m of implementation.

    Time frame: 18 months

  3. Incidence rate of all-cause hospitalisations

    Incidence of all-cause hospitalisations in eligible children aged 2-18 months with an address in a study ward, collected from hospital registration records over 18 months\* of implementation.

    Time frame: 18 months

  4. Incidence rate of clinical malaria (rebound period)

    Incidence rate of parasitologically-confirmed clinical malaria cases in children aged 19-36 months presenting to selected sentinel facilities in the 12 months following the end of the implementation period

    Time frame: 12 months following implementation

  5. Coverage of scheduled SP doses

    For each of six scheduled doses of SP, the percentage of children who received the dose in question on time or within 4 weeks following the scheduled date will be estimated for children meeting age-eligibility criteria for each dose, in a cross sectional survey after 18 months\* of implementation

    Time frame: 18 months

  6. Coverage of vaccine or vitamin A doses

    For each EPI timepoint, the percentage of children who received the vaccine/supplement in question in will be estimated for children meeting age-eligibility criteria for each dose, in a cross sectional survey after 18 months\* of implementation

    Time frame: 18 months of implementation

  7. Acceptability of PMC

    Mean PMC acceptability score using an appropriate validated instrument (Acceptability of Intervention Measure - AIM), given by caregivers of eligible children in the intervention arm, measured during the endline cross-sectional survey after 18m of implementation. (intervention arms only) Mean PMC acceptability score using an appropriate validated instrument (Acceptability of Intervention Measure - AIM\[Weiner et al 2017\]" The instrument is validated in short form to gauge respondent acceptance of a programme by answering 4 direct questions. Minimum and maximum values for this measure are 4 and 20.

    Time frame: 18 month

  8. Integration of PMC into EPI delivery platform

    Percentage of children visited in an endline cross-sectional survey who were eligible to receive SP and vaccines or vitamin A at a scheduled visit who received both an SP dose and the appropriate vaccine or Vitamin A on the same day. (intervention arms only)

    Time frame: 18 months

  9. Appropriateness of PMC

    Mean appropriateness of PMC score using a suitable validated instrument (Intervention Appropriateness Measure - IAM27), given by policymakers at local (facility), state and national level interviewed at the end of follow-up. Mean appropriateness of PMC score using a suitable validated instrument (Intervention Appropriateness Measure - IAM\[Weiner et al 2017\]"). The instrument is validated in short form to gauge degree of appropriateness (perspective of respondent) of a programme by answering 4 direct questions. Minimum and maximum values for this measure are 4 and 20. No cut-off scores for these instruments have been validated so it is recommended that full or mean scores are compared.

    Time frame: 18 months

  10. Fidelity of PMC delivery

    Mean health worker performance score based on a checklist-based survey of in-person observations of facility staff delivering PMC. (intervention arm only) Mean health worker performance score based on a checklist-based survey of in-person observations of facility\[/and CHW\] staff delivering PMC" using WHO health facility Survey manual. Min=0 max=100

    Time frame: 18months

  11. . Adoption of PMC by facilities

    Percentage of eligible intervention arm facilities surveyed that provided PMC services to children in the last 28 days. (intervention arms only)

    Time frame: 18 months

07

Study locations

1 site
  • Ministry of Health
    Oshogbo, Osun, Nigeria
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Aug 2025, 23 months after the start.

Of 96 non-industry interventional studies with no phase under Malaria, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's planned 23 months is close to that.

Counting every sponsor, half of 102 studies reached it within 23 months; a quarter within 8 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2023
First posted
Dec 4, 2023
StartActual
Aug 8, 2023
Primary completionEst.
Aug 7, 2025
CompletionEst.
Dec 2026
Last update
Dec 4, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06155448
Lead sponsor
Malaria Consortium
Collaborators
Nigerian Institute of Medical Research, London School of Hygiene and Tropical Medicine, Northwestern University
Responsible party
Sponsor
First posted
Dec 4, 2023
Start date
Aug 8, 2023
Primary completion
Aug 7, 2025 (estimated)
Completion
Dec 2026 (estimated)
Last update
Dec 4, 2023

Study contacts

James Tibenderana, PhD
principal investigator · Malaria Consortium

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion